Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shangying Hu

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|June 16, 2022
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine TrialJaimie Z Shing, Shangying Hu, Rolando Herrero, et al.
International Journal of Cancer|November 29, 2011
Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese womenJennifer S Smith, Adam K Lewkowitz, You-Lin Qiao, et al.
Cancer Communications (London, England)|January 5, 2019
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancerXiuwen Guan, Fei Ma, Chunxiao Li, et al.
Sexually Transmitted Infections|July 16, 2022
Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine TrialMónica S Sierra, Sabrina H Tsang, Carolina Porras, et al.
The Journal of Infectious Diseases|December 16, 2020
Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine TrialMónica S Sierra, Sabrina H Tsang, Shangying Hu, et al.
Human Vaccines & Immunotherapeutics|November 12, 2020
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trialShangying Hu, Xiaoqian Xu, Fengcai Zhu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 15, 2025
Relationship between age at diagnosis and recurrence characteristics in adult-onset recurrent respiratory papillomatosis: a nationwide multicenter study from ChinaQijian Zheng, Changchang Dun, Wenbin Lei, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2025
Characteristics of juvenile-onset recurrent respiratory papillomatosis in China, 2011-2021: A hospital-based nationwide studyChangchang Dun, Yutong Li, Wenbin Lei, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
International Journal of Cancer|December 13, 2024
The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort studyQi Chen, Xingmei Yao, Jiali Quan, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|June 16, 2022
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine TrialJaimie Z Shing, Shangying Hu, Rolando Herrero, et al.
International Journal of Cancer|November 29, 2011
Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese womenJennifer S Smith, Adam K Lewkowitz, You-Lin Qiao, et al.
Cancer Communications (London, England)|January 5, 2019
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancerXiuwen Guan, Fei Ma, Chunxiao Li, et al.
Sexually Transmitted Infections|July 16, 2022
Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine TrialMónica S Sierra, Sabrina H Tsang, Carolina Porras, et al.
The Journal of Infectious Diseases|December 16, 2020
Risk Factors for Non-Human Papillomavirus (HPV) Type 16/18 Cervical Infections and Associated Lesions Among HPV DNA-Negative Women Vaccinated Against HPV-16/18 in the Costa Rica Vaccine TrialMónica S Sierra, Sabrina H Tsang, Shangying Hu, et al.
Human Vaccines & Immunotherapeutics|November 12, 2020
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trialShangying Hu, Xiaoqian Xu, Fengcai Zhu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 15, 2025
Relationship between age at diagnosis and recurrence characteristics in adult-onset recurrent respiratory papillomatosis: a nationwide multicenter study from ChinaQijian Zheng, Changchang Dun, Wenbin Lei, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2025
Characteristics of juvenile-onset recurrent respiratory papillomatosis in China, 2011-2021: A hospital-based nationwide studyChangchang Dun, Yutong Li, Wenbin Lei, et al.
The Lancet. Oncology|December 3, 2020
Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine TrialCarolina Porras, Sabrina H Tsang, Rolando Herrero, et al.
International Journal of Cancer|December 13, 2024
The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort studyQi Chen, Xingmei Yao, Jiali Quan, et al.
Pageof 7